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Abstract
A tremendous interest to use nanomaterials for medical diagnosis and therapeutic
purposes has increased in the past few years. Although a lot of investigations focus
on the use of nanoparticles (NPs) for drug delivery in cancer therapies, there are
several studies investigating the potential use of NPs as carriers to detect allergies or
to alleviate inflammatory symptoms. However, although this represents a very
interesting interest and a potential avenue to use nanodrug systems, there are some
potential toxic risks. For example, cytotoxicity, oxidative stress, genotoxicity, and
inflammation have been reported both in in vitro and in vivo models for testing NPs.
In addition to medicine, a variety of other sectors, including electronics, cosmetics,
aerospace, textile industries, and even in food, used NPs. Consequently, the proba‐
bility of human exposure to NPs has risen, leading to the possibility that NPs may
reach the blood circulation and interact with immune blood cells. Therefore, it is
crucial to evaluate the risk that NPs represent to human health. In different studies
using in vivo models of inflammation, especially those investigating airway NP
exposure, an increased number of leukocytes, mainly neutrophils, in the lungs and
bronchoalveolar lavages have been reported. In fact, neutrophil counts are used as
biomarkers of inflammation. Despite this and knowing that neutrophils are key player
cells in inflammation, it is intriguing that few nanotoxicology studies have focused
on how NPs can directly alter the biology of these cells. However, an increasing
amount of studies, including some from my laboratory, demonstrate that NPs can
activate human neutrophils by different manners in vitro and can attract them or not
in vivo. The focus of this review will be to cover this new area of research.
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1. Introduction
The use of nanoparticles (NPs) has increased in the past few years in various fields, including
textile, sport, defense, aerospace, electronics, biology, medicine, etc. There is also a growing
interest to use NPs in different applications, including diagnostic technology, bioimaging, and
drug/gene delivery. Therefore, voluntary or nonvoluntary human exposure to NPs and
nanomaterials is unavoidable and will certainly expand in the near future. This has led to a
growing interest in nanotoxicology, the study of toxicity of nanomaterials. Especially, a
number of studies reported the effects of NPs on pulmonary inflammation by investigating in
vitro activation of pulmonary cells with NPs and in vivo in a variety of models in which
neutrophils appear to be the predominant leukocyte cell type in the lungs and in bronchoal‐
veolar lavages following inhalation or intratracheal instillation of NPs. It is reasonable that the
first studies focussed on pulmonary effects of NPs since inhalation is one of the major routes
of human exposure to NPs. However, even if several studies reported an increased number of
neutrophils, the literature dealing with the direct effects of given NP with neutrophils is poorly
documented and has been neglected until the last few years. In addition, since NPs are used
in a variety of sectors and are already included in several consumable products, NPs could
reach the blood stream and interact with immune cells. This review will summarize the current
literature dealing on the direct interaction of NPs with human neutrophils as well as recent
data indicating that the murine air pouch model of inflammation is suitable for evaluating the
ability of NPs to attract neutrophils in vivo.
2. Neutrophils: A brief overview
Polymorphonuclear neutrophil cells (PMNs) are important cells of the immune system
involved in host defense. In particular, they are primordial players of innate immunity and
provide a very effective defense against bacterial and fungal infections. Other than erythro‐
cytes and platelets, PMNs are the most abundant cell type in circulation, representing more
than 65 % of total leukocytes. They are terminally mature nondividing cells which develop in
the bone marrow from CD34+ stem cells, resulting from a series of cell divisions and stages as
myeloblasts, promyelocytes, myelocytes, metamyelocytes, band neutrophils, and finally,
mature neutrophils. The mechanism is still not well understood; however, this occurs under
the influence of regulatory cytokines [1-3]. It takes about 14 days to obtain fully mature
neutrophils from the CD34+ precursor cells. Of note, more than 50 % of the bone marrow is
dedicated to the generation of PMNs. A huge number of neutrophils are released from the
bone marrow. Indeed, this has been estimated at ∼5 x 1010 cells on a daily basis in a normal
adult. This represents one of the fastest cell turnovers in the human body [2, 3]. Therefore, cell
turnover must be under strict control in order to prevent diseases. The number of PMNs
remains relatively constant in healthy individuals, and this is due to the limited life span (half-
life of ∼12 h in circulation) of these cells. In addition, PMNs are known to undergo constitutive
or spontaneous apoptosis, an important step for regulating cell number. Apoptosis renders
PMNs unresponsive to extracellular stimuli and leads to expression of “eat-me” signals, some
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molecules involved in the elimination of apoptotic PMNs by professional phagocyte, a process
called efferocytosis, largely responsible for the resolution of inflammation [4-7]. Because of
this, identification of proapoptotic or antiapoptotic agents is therefore of major importance.
When the rate of PMN apoptosis is accelerated, this results in an increase in bacterial suscept‐
ibility. In contrast, when apoptosis is delayed or suppressed, this can aggravate inflammation
and lead to autoimmune disorders [4, 7].
Although different biochemical hallmarks of apoptosis, including cell shrinkage, chromatin
condensation and internucleosomal DNA degradation, appearance of pyknotic nuclei, caspase
activation, flip–flop of phosphatidylserines to the extracellular (outer) surface of the cell, etc.,
are observable in neutrophils [4, 6, 8], these cells are different from several other cell types. In
this respect, the common caspase substrates such as poly(ADP-ribose) polymerase, the
catalytic subunit of DNA-dependent protein kinase, the small ribonucleoprotein U1-70 kDa,
and the nuclear/mitotic apparatus proteins are not detected in PMNs [9, 10]. In addition,
human neutrophils do not express caspase-2 as well as the antiapoptotic Bcl-2 (B-cell lympho‐
ma 2) proteins [11]. In contrast, a predominant expression of the antiapoptotic protein myeloid
cell leukemia-1 (Mcl-1) is observed in these cells. Also, it is important to mention that PMNs
possess a very low number of mitochondria that may have a role restricted to apoptosis rather
than for energy generation [12]. During apoptosis, mature neutrophils can release proteases
from azurophilic granules, including cathepsin D, which may contribute to caspase-3 activa‐
tion through processing of caspase-8 [13]. Finally, unusual roles for nuclear proteins have been
reported in PMNs [14]. For example, unlike other cells, proliferating cell nuclear antigen
(PCNA) is expressed in the cytoplasm of mature neutrophils where it could bind to pro-
caspases, affecting their apoptotic rates.
Interestingly, both intrinsic and extrinsic pathways of cell apoptosis appear to be activated
during spontaneous human neutrophil apoptosis as evidenced, for example, by caspase-9
(intrinsic) and caspase-8 (extrinsic) activation [15-17]. More recently, increasing evidences
indicate that the endoplasmic reticulum (ER) stress-induced cell apoptotic pathway is also
operational in human PMNs [18, 19]. These cells were found to express inositol-requiring
protein-1 (IRE1), activating transcription factor-6 (ATF6), and protein kinase RNA (PKR)-like
ER kinase (PERK), the three major sensors of protein folding status in the ER [20, 21].
During acute inflammation, PMNs are the first type of leukocytes to migrate to an inflamma‐
tory site, where they will produce several proinflammatory mediators including chemokines
that first attract other PMNs and then other cell types like monocytes–macrophages and
lymphocytes, corresponding to chronic inflammation. PMNs are phagocytes well recognized
for their ability to eliminate invading pathogens via two important mechanisms: i) the
respiratory burst, which is an oxygen-dependent process leading to the generation of reactive
oxygen species (ROS), and ii) degranulation, an oxygen-independent mechanism by which
PMNs release potent toxic degradative products stored in granules. In addition to reactive
oxygen metabolites and granule enzymes, PMNs are known to be an important source of
products implicated in tissue damage and inflammation such as leukotriene B4, platelet-
activating factor, and various cytokines (IL-1α, IL-8, IL-12, TNF-α, TGF-β, GRO-α), to name a
few [1]. The importance of PMNs in inflammation is further supported by the observation that
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various PMN priming and activating agents such as IL-1β, IL-8, IL-15, GM-CSF, TGF-β, C5a,
C9, etc., are present, for example, in the synovial fluids of rheumatic patients [22-24]. PMNs
are also known to adhere onto cell substratum (e.g., endothelial cells) [25] or onto extracellular
matrix proteins, including fibronectin [26]. Finally, PMNs can move toward a chemotactic
gradient (chemotaxis) and exert phagocytosis, two important functions involved in killing and
eliminating pathogens. About ten years ago, an important new discovery was made concern‐
ing the biology of neutrophils; upon activation, these cells were found to release neutrophil
extracellular traps (NETs) composed of decondensed chromatin DNA in association with
histones, granular proteins, and a few cytoplasmic proteins [27]. NETosis, a sort of PMNs
suicide-generating NETs, was identified as a novel antimicrobial mechanism able to kill
extracellular bacteria, fungi, and parasites.
It is important to mention that the same arsenal and biological responses of PMNs discussed
above that are involved in host defense can also be deleterious for an organism when dereg‐
ulation occurs. This phenomenon is known as the neutrophil paradox. Because of this, and
knowing the role of PMNs during inflammation (PMNs are seen as conductors of inflamma‐
tion), it is very important to carefully understand the mode of action of PMN agonists as well
as to identify new ones, including the new actors, NPs. Because how NPs interact with PMNs
is an area of research that is still in infancy and that a lot of work needs to be done, it is important
to determine how a given NP will alter or not several PMN functions in order to obtain a
general picture rather than investigating only one or two functions. Also, even if an agent is
not a direct PMN agonist by itself, it can be indirectly proinflammatory by attracting these cells
in vivo, as is the case with the cytokine IL-21 [28]. This aspect needs also to be studied with
NPs. For this reason, the following sections will describe how several PMN functions can be
studied in vitro. Of note, several techniques and methods can be used to determine a given
PMN function; but for clarity and simplicity, I will describe those that are used by several
laboratories, especially the assays that are routinely used in mine. In addition to this in vitro
aspect, I will described how we performed the murine air pouch model, a model recently
proposed by a consortium of 18 researchers from six different countries, as a future standard
assay for testing NPs in vivo [29].
3. Evaluating neutrophil functions In vitro
3.1. Neutrophil source
The first step for investigating neutrophil cell biology is to have access to a PMN source.
Although some researchers, including ourselves, used immature human cell lines such as
HL-60 and PLB-9895, these cells are not primary neutrophils and may respond differently [30].
Others used rodent PMNs for investigating the role of different agents on neutrophil biology.
However, it is important to remember that unlike humans where more than 65–70 % of
circulating leukocytes are neutrophils, this proportion do not exceed ∼25 % in rodents [31]. In
addition, although methods for human neutrophil isolation are now standardized, similar
procedures for isolating PMNs from nonhuman species are not as well developed. Because
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PMNs are very reactive cells, the method of isolation is extremely important to avoid cell
activation during the isolation process. In respect with this, different techniques have been
proposed [32] for isolating highly purified PMNs from large animals (bovine, equine, ovine),
small animals (rodents, rabbit), and nonhuman primates (macaques). In my laboratory, we are
using human blood as a source of neutrophils and we freshly isolate them in order to perform
several studies, including the role of chemicals of environmental concern [30, 33-35], plant
lectins and extracts [36, 37], cytokines [28, 38-46], myeloid-related proteins [47-49], different
other compounds [19, 50-55], and, more recently, NPs [56-59]. Blood is obtained from healthy
consenting individuals according to institutionally approved procedures, but it is also possible
to isolate PMNs from blood of patients suffering from a given disease for comparison with
age- and sex-matched healthy individuals.
3.2. Cell viability, necrosis, and purity
It is important to evaluate cell viability immediately after PMN cell isolation. We propose to
determine this by the trypan blue exclusion assay since, during this method, it is also possible
to simultaneously evaluate if cells are activated (irregular cell shape) or not (round or spherical
shape) following the isolation procedure. In addition, it is mandatory to evaluate cell viability
over time, especially after 24 h of incubation, since the rate of apoptotic PMNs is normally in
the range of 30–50 % without addition of any exogenous agents. Moreover, apoptotic PMNs
are known to exclude trypan blue and are thus considered “viable” and not necrotic. In parallel,
we strongly suggest to evaluate neutrophil purity that could be verified by cytology from
cytocentrifuged preparations colored with Hema-3 stain set, a procedure allowing a differen‐
tial count. We never performed experiments with samples having ≥ 3 % eosinophils, the most
contaminant cell type observed in our preparations. Other methods can also be used to
evaluate cell viability, such as the determination of the release of lactate dehydrogenase (LDH)
measured by a colorimetric assay and the dimethylthiazolyl-diphenyltetrazolium (MTT)
reduction assay. Several commercially available kits exist; however, it is mandatory to first
verify if a given NP could interfere with the assay to avoid false assessment of toxicity
[60-62].
3.3. Cell shape changes
Naive non-activated neutrophils possess a round or spherical shape [41]. To study the effect
of a given agent on neutrophil activation, cells have simply to be incubated in the presence of
the molecule of interest, and morphological examination is monitored over time by optical
microscopy [41, 58].
3.4. Actin polymerization
Actin is a cytoskeletal protein involved in several (if not all) PMN functions. It is possible to
study its polymerization as a marker of neutrophil activation [63] where actin monomer (G-
actin) will be reorganized to form, for example, filaments or F-actin. To do so, PMNs are
incubated for short periods of time (normally from 0 to 30 min) at 37 oC with buffer (control)
or with a molecule of interest in a final volume of 100 μL. Synthetic peptide N-formyl-
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methionyl-leucyl-phenylalanine (fMet-Leu-Phe) is used as a positive control for the assay [36].
After incubation, digitonin and paraformaldehyde are used for permeabilization and cell
fixation, respectively, and then PMNs are washed twice by centrifugation and incubated with
phalloidin-FITC (binds to filamentous of actin) for 20 min at 4 oC (light protected) prior to
FACS analysis.
3.5. Expression of tyrosine phosphorylated proteins
Another manner to determine rapid PMN activation by a given agent is to determine its
potential induction of phosphorylation events, especially tyrosine phosphorylation [44, 48].
This consists of incubating PMNs with a given agent for several short periods of time (typically,
30–60 s and 5, 15, and 30 min), and then the reaction is stopped by adding Laemmli’s sample
buffer, as described previously [30, 48]. Aliquots corresponding to a desire number of cells (we
are using normally 1 x 106 cells) are then loaded onto 10 % SDS–PAGE and transferred from
gel to a nitrocellulose or polyvinylidene difluoride membrane and nonspecific sites are treated
with a blocking solution [48]; the membrane is then washed and incubated with monoclonal
anti-phosphotyrosine antibody. The membrane is washed and incubated with a horseradish
peroxidase-conjugated anti-mouse IgG + IgM antibodies for about 1 h, and, after washing,
phosphorylated bands are revealed with ECL Western blotting detection system. In our hands,
protein loading is verified by probing the membrane (after stripping) with an anti-β-actin or
anti-GAPDH antibody and/or by staining the membranes with Coomassie blue at the end of
each experiment.
3.6. Neutrophil adherence assay
Adhesion of PMNs is an important biological response involved during inflammation. This
response could be studied by several ways. In my laboratory, we determine the capacity of
PMNs to adhere onto a cell substratum using the well-characterized human epithelial A549
cells [64]. Briefly, after obtaining the desired confluence of A549 cells grown onto coverslips,
PMNs (pretreated or not with a given agent for a desire period of time) are stained for 30 min
with calcein AM and incubated with A549 cells. The number of adherent PMNs are then
calculated by counting the number of fluorescent cells from five randomly selected high-power
fields, as previously published [43, 64].
3.7. Chemotaxis
Chemotaxis of human PMNs could be easily studied using a Boyden chamber assay. The
bottom wells are loaded with buffer or agonists to be tested (typically in a final volume of 25
μl), the membrane is then placed over the wells, and the top layer of the chamber is added
over the membrane. Cells (in 50 μl) are added to the top chamber wells, and the chamber is
incubated at 37 °C for a given period of time (normally 0–60 min) in a humidified incubator
in the presence of 5 % CO2. After the incubation, the top of the chamber is removed and the
upper side of the membrane is wiped carefully with the rubber scraper furnished by the
manufacturer. Then, the membrane is fixed in methanol, colored with Hema-3 stain kit,
mounted on a glass slide, and examined under oil immersion at 400 x. The details of the
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procedure have been previously published [65, 66]. In this assay, the potent neutrophil
chemokine CXCL8 (IL-8) is used as a positive control [67].
3.8. ROS generation
3.8.1. Superoxide production
Several assays can be used to evaluate ROS generation by human PMNs. Since the major source
of ROS in PMNs occurred after NADPH oxidase activation leading to superoxide production
(O2-), we routinely used the colorimetric assay based on reduction of cytochrome c, as previ‐
ously published [48, 51]. Briefly, PMNs (1 x 106 cells/ml) are suspended in buffer supplemented
with 1.6 mM CaCl2 with or without 10 μg/ml superoxide dismutase (SOD) with 130 μM
ferrocytochrome c for 5–90 min at 37 °C in the presence of various concentrations of the agonists
to be tested or phorbol 12-myristate 13-acetate (PMA) at 10-7 M, used as a positive control. The
reduction of cytochrome c is then monitored at 550 nm, and the concentration of O2- anions
produced is calculated by the difference between corresponding wells with or without SOD
using an extinction coefficient of 21.1.
3.8.2. Detection of intracellular ROS
Flow cytometry is frequently used to measure ROS production. Using different probes, we can
evaluate the production of ROS mainly originating from the mitochondria or endoplasmic
reticulum, depending on the probe used. We routinely used the CM-H2DCFDA probe and
measured the fluorescence with a FACScan. ROS production is expressed as mean fluorescence
intensity (MFI) [48].
3.9. Degranulation
Degranulation is one of the most important functions exerted by PMNs for the defense of an
organism. Following activation, PMNs will rapidly release potent degradative enzymes and
several receptors involved in the recognition and ingestion of pathogens. These products are
localized in different kinds of granules: azurophil, specific/gelatinase, and secretory granules
[68, 69].Because granules will fuse with the cytoplasmic membranes and release some products
on the cell surface and then in the external milieu, it is possible to study in the laboratory the
cell surface expression of markers of the different types of granules [70]. Therefore, we
routinely determine the cell surface expression of CD35, CD63a, andCD66b by flow cytometry,
since these molecules are specific markers of azurophil, specific/gelatinase, and secretory
granules, respectively [47, 53, 56]. Excellent antibodies to these markers are commercially
available.
Although the expression of the above markers could be increased (or not) at the PMN cell
surface after stimulation, it is also important to determine if a protein known to be expressed
in a given type of granule is released into the external milieu. To do so, we harvested the
extracellular milieu after several periods of time following stimulation and performed Western
blot experiments using antibodies specific for myeloperoxidase (azurophil), matrix metallo‐
proteinase-9 or MMP-9 (specific/gelatinase), or albumin (secretory). The details of the protocol
have been previously described [47, 53].
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Even if a given granule product is released by activated PMNs into the external milieu, it is
interesting to know also if an enzymatic activity could be preserved in the fluids. To test this,
we performed zymography assay. After stimulation of human PMNs, cells are centrifuged at
13,000 rpm for 10 min at 4 °C and the pellets are discarded. The supernatants (10–50 μl,
corresponding to 50,000 cells) are then mixed with a nonreducing buffer (40 % glycerol, Tris-
HCl 1 M, pH 6.8, SDS 8 %) and separated on 10 % acrylamide gels containing 0.2 % gelatin.
Gels are washed twice for 30 min with 2.5 % Triton X-100 and incubated overnight in digestion
buffer (Tris-HCl 50 mM, pH 7.4, NaCl 150 mM, CaCl2 5 mM). The gels are stained with
Coomassie blue 0.1 % and then destained. Densitometric analysis is performed to quantify the
intensity of the white zones corresponding to gelatinase activity digesting gelatin incorporated
into the gel [47, 53, 71].
3.10. Phagocytosis
Our preferred technique for evaluating PMN phagocytosis consists of the ingestion of
opsonized sheep red blood cells (SRBCs). In this assay, PMNs are treated with a given agent
or the corresponding buffer for a given period of time and cells are incubated with SRBCs
pretreated with a final 1/200 dilution of commercially available rabbit IgG anti-SRBCs for 30–
45 min at 37 °C in a 1:5 ratio. The samples are centrifuged 200 x g at 4 °C for 10 min. Supernatants
are discarded and, to eliminate noningested SRBCs, the pellets are treated with 300 μl of H2O
for 20 s followed immediately by the addition of 4.5 ml ice-cold PBS [45, 48, 54, 72]. After
washing, the final pellets are suspended to a final concentration of 10 x 106 cells/ml. Duplicate
cytocentrifuged preparations are then stained with Hema-3 stain kit, and the phagocytosis rate
is determined by counting the number of PMNs ingesting at least one opsonized SRBC.
3.11. Apoptosis
Apoptosis can be evaluated by several different methods. We routinely determine the
apoptotic rate of human PMNs by two assays in parallel, by cytology and flow cytometry [37,
38, 40, 44, 51, 73]. For both assays, freshly isolated human PMNs are incubated (10 x 106 cells/
ml in RPMI-1640 supplemented with 10 % autologous serum) at 37 °C in 5 % CO2 in 96-well
plates for 24 h with a given agonist and its corresponding buffer/vehicle. Cells are then
harvested to perform the assays as follows.
3.11.1. Cytology
For cytology, cells are cytocentrifuged on microscope slides, stained with the Hema-3 staining
kit and examined by light microscopy at 400x final magnification. Apoptotic neutrophils are
defined as cells containing one or more characteristic darkly stained pyknotic nuclei. Results
are expressed as the percentage of PMNs in apoptosis.
3.11.2. Flow cytometry
For the flow cytometric procedures, PMNs are stained with FITC annexin-v or an FITC
antihuman CD16 antibody. During apoptosis, the flip–flop of phosphatidylserines occurred,
leading to their expression at the cell surface. Since annexin-v possesses a very high affinity to
bind to phosphatidylserines, apoptotic cells will be positive to FITC annexin-v. In this assay,
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propidium iodide can also be used to measure cell necrosis in parallel. In contrast, cell surface
expression of CD16 (that is very high in normal PMNs) is lost during PMN apoptosis resulting
from CD16 shedding.
3.12. Cytokine production
PMNs are known to produce several cytokines [74]. There are several different approaches
that can be used to measure the production of cytokine. We prefer to study production of
cytokine at the protein level. We used an antibody array assay for screening purpose and then
quantified a given cytokine by ELISA. For both assays, supernatants of activated PMNs are
harvested and used for the detection of cytokines. When fluids are frozen, we normally use
them within three weeks after the experiments to eliminate possible cytokine/chemokine
degradation occurring over time.
3.12.1. Antibody array: Proteome profilertm array
We used a commercially available human cytokine array panel for the screening purpose. All
the steps for the detection of different analytes are performed following the manufacturer
recommendation and as previously described [50, 75]. To detect the different analytes
(cytokines/chemokines), we used pooled supernatants harvested from neutrophils (10 x 106
cells/ml in RPMI1640-HEPES p/s supplemented with 10 % autologous serum) treated for
different periods of time with buffer (negative control) and LPS (positive control) or with the
tested agents to probe the membranes. The chemiluminescent signal from the bound analytes
present in the supernatants is then detected on Kodak X-OMAT-RA film. The signal intensity
of each analyte (in duplicate) is normalized to the membrane’s positive controls. Protein array
membranes are scanned and densitometric analysis is performed using the AlphaEaseFC
(FluorChem HD2) software.
3.12.2. ELISA
The measurement of a given cytokine/chemokine (such as IL-6/IL-8) is determined with
commercially available specific enzyme-linked immunosorbent assay (ELISA) kits. Neutro‐
phils are incubated as above in a 96-well plate, and the supernatants are harvested, centrifuged,
and stored at -80 °C for no more than three weeks before performing ELISA. Unlike the
antibody array assay described above, each supernatant (normally at least from five different
blood donors) is used to quantify the amount of the tested analyte.
3.13. De novo protein synthesis
Cells (10 x 106 cells/ml in RPMI-1640 medium supplemented with 10 % autologous serum)
are metabolically labeled with 4.625 MBq of the Redivue Pro-Mix L-[35S] in vitro cell labeling
mix in the presence or absence of a given agonist or with 1–10 μg/ml cyclohexymide (CHX),
an inhibitor of protein synthesis, or a mixture of both the agonist and CHX for 24 h [38,
41, 51, 76]. Cells are then harvested, and cell lysate is prepared for SDS–PAGE as previous‐
ly  described.  After  electrophoresis,  gels  are  stained  with  Coomassie  blue  (to  verify
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equivalent loading),  dried, and exposed with Kodak X-OMAT-RA film at -80 °C for 1–3
days. Absence of new polypeptides is observed in the lanes where the cells were treated
with CHX.
4. Evaluating PMN infiltration In vivo
Several  animal  models  of  inflammation  have  been  developed over  the  years.  Some are
suitable for understanding the mechanisms involved in the development of inflammatory
diseases.  The collagen-induced arthritis  model  is  a  good example [77-79].  Other  models
focus on pulmonary inflammation, including mouse models of allergic asthma. Typically,
in this  latter  model,  animals are sensitized to a  foreign antigen by intraperitoneal  injec‐
tion in  the  presence  or  absence  of  an  adjuvant.  After  the  sensitization period,  mice  are
challenged with the antigen directly in the lungs or the nose, and airway inflammation is
then elicited. Although PMNs are known to exert some pathological effects during arthritis
and in some cases during asthma, the observed cells in these models are not necessarily
PMNs, but rather mainly some lymphocytes and eosinophils in collagen-induced arthritis
and asthma models, respectively. However, in several other inflammatory models where a
given agent is administered by inhalation, intratracheally or directly into lungs, PMNs will
be easily observed in the bronchoalveolar lavages or lungs. However, these models are time
consuming, are not the cheapest, and, in addition, necessitate a certain degree of techni‐
cal skills. The rodent air pouch model of acute inflammation is probably the best, simple,
not time-consuming, and cheapest model for monitoring leukocyte influx, including PMNs.
This model has been used for investigating the inflammatory activity of a large number of
compounds,  including cytokines  [28,  43,  80],  plant  extracts  and lectins  [81-83],  different
drugs [84-86], etc.
4.1. Murine air pouch
Several  kinds  of  mice  can  be  used  to  perform  this  model.  For  screening  purpose,  we
recommended to use outbred CD-1 mice since they are less expensive than other inbred
mice. Normally, we use female mice (6−8 weeks of age). A period of acclimation of about
one week is allowed to animals prior to initiation of the experiments. On days zero and
three, mice are anesthetized with isoflurane, and 3 cc of sterile air was injected subcutane‐
ously, in the back, with a 26-gauge needle to form an air pouch as published previously.
On day six, 1 mL of buffer control (HBSS or PBS) or an increasing concentration of a given
compound is injected directly into the air pouch. Mice are then killed by CO2  asphyxia‐
tion 3, 9, 12, or 24 h after the treatment, and the pouches are washed once with 1 ml and
then twice with 2 ml of buffer containing 10 mM EDTA. Exudates are centrifuged at 100
X g for 10 min at room temperature, and supernatants are collected and stored at -80 °C
for further analysis.  Cells  are resuspended at  0.5  x 106  cells/ml,  spread onto microscope
slides, and stained with Hema-3 stain kit for identification/quantification of leukocyte cell
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subpopulations. The details of the model have been previously discussed [28, 35, 50, 87,
88]. Interestingly, several kinetics could be done with this model as well as several different
experiments using the exudates such as the determination and quantification of different
soluble factors including cytokines and chemokines. Moreover, the exudates could be used
to perform zymography experiments to determine, for example, gelatinase activity. After
centrifugation of the collected exudates, cells can also be incubated in vitro for studying
the different PMN functions, especially in an experimental condition such as LPS-induced
murine air pouches, where more than 85 % of cells are PMNs. It is also possible to purify
a given type of leukocyte before performing in vitro assays. In brief, this model allows a
panoply of different experiments. For example, we have used this model to demonstrate
that an intraperitoneal administration of curcumin, prior to LPS-induced air  pouch, was
able to inhibit the proinflammatory effect induced by LPS [50].
5. Nanotoxicology and PMNs
While NPs have great potential  for human needs,  there are increasing concerns that the
same features that make them so attractive and interesting also represent potential risks to
human health [89]. Consequently, a new branch of toxicology, nanotoxicology, has recently
emerged. Nanotoxicology could be defined simply as a discipline evaluating the role and
safety of NPs on health. Exposure to NPs has increased dramatically in the past few years
due to anthropogenic sources given that NPs can be formed via a wide variety of processes/
methods.  These  sources  are  numerous  and include  internal  combustion  engines,  power
plants, and many other sources of thermodegradation [90]. Furthermore, intense research
and  development  by  the  industry  and  academia  multiply  the  number  of  individuals
potentially exposed to NPs. Nanotoxicology is,  therefore, a very complex discipline, and
the  diversity  and  complexity  of  NPs  makes  chemical  characterization  not  only  more
important but also more difficult [91].
One of  the most  adverse effects  of  NPs reported in the literature is  certainly inflamma‐
tion. A variety of NPs were found to possess proinflammatory activities, principally based
on their ability to increase the production of different proinflammatory cytokines [92-95]
and  on  the  observations  that  NPs  can  exacerbate  airway  inflammation  in  vivo  [96-99].
However,  as  previously mentioned,  inflammation is  a  normal biological  response of  the
body  to  various  assaults,  including  microorganisms,  injuries,  dusts,  drugs,  and  other
chemicals. Under normal circumstances, inflammation will subside and resolve itself in a
healthy  individual  through  a  series  of  tightly  regulated  responses.  However,  when
deregulation  occurs,  inflammation  can  lead  to  inflammatory  disorders  and  diseases
including asthma and several pulmonary lung diseases, dermatitis, arthritis, inflammato‐
ry bowel diseases, etc. [1, 100]. Curiously, despite the importance of PMNs in inflamma‐
tion  and  since  several  studies  reported  an  increased  number  of  PMNs  in  NP-induced
pulmonary inflammation, there are few studies investigating the direct effects of NPs and
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their mode of action in PMNs. The following sections will cover different studies that have
been done regarding the effects of some NPs on PMN cell physiology.
6. Interaction between nanoparticles and human PMNs
6.1. Interaction between nanoparticles and human PMNs: Not so novel finally
Probably the first study reporting a direct effect of NPs with human neutrophils was done
more than 25 years ago where Hedenborg published in 1988 that titanium dioxide (TiO2) dust
induced the production of ROS by human neutrophils as measured by a chemiluminescence
assay [101]. Different dust particles (ranging in size from 345 to 1,000 nm) were tested, and
none of them were cytotoxic, as assessed by lysozyme release or trypan blue exclusion [101].
It was concluded that TiO2 stimulated the chemiluminescence activity of PMNs in a concen‐
tration-dependent manner and that particle size and surface structure of the dust were
important for determining the intensity of the response. Although the nanomaterial used for
this study was not-typical NPs based on the definition that the three dimensions need to be
smaller than 100 nM, the size was still in the nanometer range. In fact, the definition of an NP
is complex, and according to the 2011 Commission of the European Union, the definition of
an NP is: “a natural, incidental or manufactured material containing particles, in an unbound state or
as an aggregate or as an agglomerate and where, for 50% or more of the particles in the number size
distribution, one or more external dimensions is in the size range 1-100 nm.” Therefore, according
to such a definition, a “nano” object needs only one of its dimensions, <100 nm, to be classified
as an NP, even if its other dimensions are not in that range. Strictly based on the nanometer
terminology, one can define any objects in the nm range as a nanoparticle or at least as a “nano”
object as was the case with this study investigating the effect of TiO2 dust.
6.2. Studies from different laboratories
The next section will cover studies investigating the direct interaction between NPs and human
neutrophils. Before describing works performed by others, I would like to mention that if some
studies have been forgotten, this is completely unintentional on my part. Also, it is important
to specify that few studies reported the effects of NPs on nonhuman neutrophils, including
fish [102, 103] and rat [104] PMNs that are not part of this present review. Nevertheless, in
brief, the results indicate that TiO2 NPs stimulated oxidative burst and NET release in fathead
minnow PMNs [102], whereas fullerenes were found to inhibit oxidative burst and suppressed
the release of NETs and degranulation of primary granules [103]. In rats, poly(lactide acid) or
PLA nanoparticles were reported to be more efficiently phagocytosed than PLA/poly(ethylene
glycol) or PEG blends [104].
In one study, human PMNs incubated with increasing concentrations of polymethylmetha‐
crylate (PMMA) NPs (50–60 nm) in vitro were found to release lactate dehydrogenase,
lysosome, and beta-glucuronidase in a dose-dependent fashion [105]. In contrast, PMMA NPs
diminished migration of PMNs in a dose-dependent manner, as assessed by measuring the
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distance attained by the leading front of cells in Boyden chambers. Interestingly, polystyrene
beads (50 nm in diameter) were employed as a physical control throughout the study, and they
were also found to affect the same PMN functions as compared with cells incubated with the
buffer alone, but the intensity of the response was inferior to that of PMMA NPs.
In 1996, using solid lipid NPs (SLN) produced by high-pressure homogenization of melted
lipids (glycerolbehenate, cetylpalmitate), Müller and colleagues modified the surface of these
NPs with hydrophilic poloxamine 908 and poloxamer 407 block copolymers and found slightly
different results regarding the phagocytic uptake and cell viability of human PMNs [106].
Interestingly, cell viability was ≥ 80 % for all studied NPs with a diameter ranging from 123 to
246 nm, as assessed by the colorimetric MTT assay. Modification of the solid lipid NPs with
poloxamine 908 and poloxamer 407 reduced phagocytic uptake to 8–15 % of hydrophobic
polystyrene particles. The same team also reported, in another study, the in vitro cytotoxicity
of SLN as a function of lipid matrix and stabilizing surfactant not only in mature PMNs but
also in human promyelocyte HL-60 cells. These latter cells, which can be differentiated in
laboratory toward neutrophil-like cells with dimethyl sulfoxide, were used for comparison
with fully mature PMNs isolated from the blood of healthy volunteers. The aim was to use
this cell line to replace the daily PMN isolation that is costly and time consuming. They
reported that the nature of the lipid had no effect on PMN and HL-60 cell viability. However,
some distinct differences were found for the surfactants. For example, binding of poloxamer
184 to the SLN surface reduced the cytotoxicity of the surfactant by a factor of ~65. They
concluded that HL-60 cells represented a potentially good model for replacement of primary
PMNs. In addition to HL-60, PLB-985 cells can also be driven by chemical treatment into
“neutrophil-like cells but, as we previously documented, both cell lines can respond differently
than PMNs [30, 107]. Therefore, I believe that results obtained from “real” human mature
PMNs are more easily interpretable for the evaluation of human risk.
The cytotoxicity of injectable cyclodextrin nanoparticles/nanocapsules (specifically, β-CDC6)
in mouse L929 fibroblasts and human PMNs has been determined in one study [108]. The
cytotoxicity was evaluated in the presence or absence of PF68, the most commonly used
surfactant in NP formulations and designed to be potentially utilized as an injectable nanosized
drug carrier. Depending on the formulation, the particle size distribution was between ~110
and 350 nm. Using MTT assay, it was concluded that β-CDC6 NPs do not exert a significant
cytotoxicity against both types of cells. Of note, although the experimental conditions were
appropriate for fibroblasts (three days before performing the assay), this is not necessarily the
same for human PMNs known to spontaneously undergo apoptosis when incubated in vitro;
about 50 % of PMNs are already in apoptosis after only 24 h [4, 37]. In 2006, the effects of
cholesteryl butyrate (chol-but) solid lipid NPs and PMNs were investigated [109]. In vitro
incubation of PMNs with 10-8-10-4 M cholesteryl butyrate solid lipid nanoparticles (chol-but
SLNs, mean diameter of 130–160 nm) for 10–240 min did not lead to cytotoxic effects as
determined by the trypan blue exclusion assay [109]. Chol-but SLNs were found to inhibit
adhesion of PMNs onto fetal calf serum-coated plastic wells as well as onto human umbilical
vein endothelial cells. Also, in this study, the ability of FMLP-induced O2- production and
FLMP-induced MPO release by PMNs was inhibited by chol-but SLN. More recently, the
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capacity of human immune cells to internalize rod-shaped and spherical gold NPs (AuNPs),
with diameters of 15–50 nm and a variety of surface chemistries, has been determined.
Interestingly, in contrast to monocytes–macrophages that were found to ingest AuNPs [110],
PMNs rather “trap” them in NETs [111]. The cell-gold networks, already observed after 15 min
of treatment of immune cells with the AuNPs, were predominantly observed in PMNs and, to
a lesser extent, in monocytes and macrophages. This indicates that NETs act as a physical
barrier for NPs. In addition, in this study, the authors demonstrated that the particle shape is
not very important for particle trapping, whereas the positive charges significantly enhance
this phenomenon [111]. Influence of AuNPs on activation of human PMNs was also investi‐
gated in another study where AuNPs with a size of 60 nm were found to induce generation of
free radicals as assessed by a chemiluminescence assay [112]. The authors proposed that the
influence of AuNPs on the membrane surface potential of PMNs was most likely the mecha‐
nism involved.
Interaction between silver nanoparticles-polyvinyl-alcohol (AgNPs-PVA) and human PMNs
was recently investigated. In this study, PMNs were incubated in the presence of 10 μM of
AgNPs-PVA, and the increased ROS production was determined by flow cytometry using the
DCFH-DA probe [113]. Curiously, in this study, the authors determined necrosis and apoptosis
by flow cytometry after staining with PI and annexin-v in human hepatocellular carcinoma
(HepG2) and in peripheral blood mononuclear cells (PBMCs), but not in PMNs. Both cell
necrosis and apoptosis were significantly increased after treatment with the NPs. Further, they
investigated cellular uptake in HepG2 and PBMCs based on increased SSC fluorescence
intensity recorded by flow cytometry, but, again, not in human PMNs.
Several PMN functions, including viability, chemotaxis, phagocytosis, oxidative burst, and
cytokine production (IL-1β, IL-6, and IL-8), were investigated in response to an immunosup‐
pressive agent sirolimus (SRL) alone, SRL-loaded poly(d,l-lactide) nanoparticles (SRL-PLA-
NPs), and plain PLA-NPs [114]. While phagocytic activity was markedly reduced, but
recovered within 3 h, the other tested PMN functions were not affected.
In their study, Haase et al. (2014) compared the effects of AgNPs and ionic silver (Ag+) on cells
of the innate immune system, in particular on PMNs and macrophages [115]. They generated
five kinds of AgNPs (diameters ranging from 2 to 35 nm) and did not observe any impact on
phagocytosis, oxidative burst, as well as activation of the TNF-α promoter. In contrast, AgNPs
and Ag+ were found to induce NET release and to inhibit the formation of nitric monoxide.
Also, both AgNPs and Ag+ were found to increase intracellular ROS levels as well as the second
messenger Zn2+. Therefore, based on these data, the effect of AgNPs on human PMNs is not
specific to the particles since they are also observed with Ag+.
6.3. Our involvement in studying interaction with NPs and human PMNs
Our laboratory has been interested in investigating the role of NPs on the biology of human
PMN because one of the most reported adverse effects of NPs after administration in animals
or when incubated in vitro in different type of cells is inflammation, our main expertise. Of
note, we voluntary use unloaded, naked, or plain engineered NPs in our present studies based
on the fact that several kinds of NPs are commercially available and since we believe that it is
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important to first establish how human PMNs will react with a given NP before trying to use
this latter as potential carrier for drug delivery, for example. In addition, since these NPs are
relatively easy to obtain and that several of them are probably already used by workers in
different kinds of industries, it is warranted to understand their mode of action as they are
handled and/or used by individuals. The first study was published in 2010, indicating that our
involvement in this area of research is recent [57]. We investigated how human PMNs respond
to TiO2 NPs since these NPs were (and are still) the most studied NPs reported in the literature.
We used a commercially available preparation of TiO2 NPs (anatase crystals) of 1–10 nm in
size, as determined by transmission electronic microscopy (mentioned in the technical data
sheet and also confirmed by us). We first incubated freshly isolated human PMNs with
increasing concentrations of TiO2 NPs (0–800 μg/ml) over time and determined their potential
cytotoxicity. As assessed by trypan blue exclusion assay, the NPs did not decrease cell viability
and only a small portion ≤ 3 % of cells were in necrosis after 24 h of incubation at the highest
concentration tested. We next determined if TiO2 NPs could induce morphological cell shape
changes in PMNs, an indicator of cell activation. After 24 h, the optimal concentration inducing
cell shape changes was 100 μg/ml, a concentration used by others with human lymphocytes
[116]. Others reported the use of TiO2 NPs up to 4,000 μg/ml for in vitro studies, but in U937
human monoblastoid cell line [117]. Interestingly, we demonstrated that TiO2 NPs were able
to induce rapid tyrosine phosphorylation events in PMNs as quickly as 15 s, with a maximal
effect at 1 min of treatment. More specifically, we identified Erk-1/2 and p38 MAP kinases, the
two major enzymes involved in different PMNs functions, as targets of TiO2 NPs [57].
Concordant with our data indicating TiO2 NPs were not cytotoxic, we reported and demon‐
strated that they significantly inhibited PMN apoptosis. Using an antibody array assay
allowing the simultaneous detection of different cytokines/chemokines, TiO2 NPs were found
to increase the production of 13 analytes, including IL-8 and Gro-α, two potent neutrophil
activators. They exhibited the greatest increase (~16 times and ~4 times more vs control cells,
respectively). Because antibody assay is a semiquantitative assay, we next confirmed that
TiO2 NPs increased IL-8 production by quantitative ELISA. Taken together, these results
clearly indicate that TiO2 NPs are neutrophil activators.
In another study, we focused our attention on the human PMN degranulation process not only
in response to TiO2 NPs but also after treatment with two other metal oxide NPs, zinc oxide
(ZnO) and cerium dioxide (CeO2) [56]. This was probably the first study investigating the effect
of NPs on degranulation. Because TiO2 was previously found to activate PMNs, we first
determine whether or not ZnO and CeO2 NPs could be neutrophil modulators. We found that
all NPs (having the size of 1–10 nm) were able to activate PMNs, based on induction of actin
polymerization. As assessed by flow cytometry, the three types of NPs slightly downregulated
cell surface expression of the granule marker CD35 but increased CD66b and CD63 expression.
In addition, the protein expression of myeloperoxidase, MMP-9 and albumin stored in
azurophil, specific/gelatinase, and secretory granules, respectively, was significantly increased
in the supernatants of NP-induced PMNs vs supernatant from untreated cells. Also, both
TiO2 and CeO2 were found to markedly increase the enzymatic activity of MMP-9 released into
the supernatants, as determined by gelatin zymography. ZnO NPs were found to only exert a
modest effect in these experiments. Therefore, the three NPs can differentially affect all steps
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involved during neutrophil degranulation, namely, cell surface expression of granule markers,
liberation of proteins in the supernatants, and enzymatic activity [56].
We next examined the role of AgNPs with a starting size of 20 nm (AgNP20) on human PMN
apoptosis. Treatment of PMNs with AgNP20 results in increased cell size, and TEM experiments
revealed that AgNP20 can rapidly interact with the cell membrane, penetrate inside neutro‐
phils, localize in vacuole-like structures, and be randomly distributed in the cytosol after 24 h
[59]. Treatment with 100 μg/ ml AgNP20 for 24 h (but not 10 μg/ml) increased the PMN
apoptotic rate as determined by cytology and by flow cytometry after staining with FITC
annexin-v. Also, AgNP20 was found to inhibit de novo protein synthesis as demonstrated by
gel electrophoresis of metabolically [35S]-labeled cells as strong as the potent protein inhibitor
cycloheximide. Therefore, AgNP20 was identified as potent PMN proapoptotic agents.
Preliminary experiments indicate that AgNP70 (70 nm), in contrast to AgNP20, delays human
PMN apoptosis (our unpublished data) in agreement with the fact that an NP with a different
size (here 20 vs 70 nm) can act completely different.
Based on these results, we were interested in investigating more in depth how ZnO NPs can
alter human PMN biology. We demonstrated that ZnO increased the cell size, induced cell
shape changes, activated phosphorylation events, and enhanced cell spreading onto glass, but
did not induce the generation ROS [58]. In contrast to AgNP20, treatment of PMNs with ZnO
markedly and significantly inhibited apoptosis and increased de novo protein synthesis.
Utilization of cycloheximide reversed not only the ability to increase de novo protein synthesis
but also the antiapoptotic effect of ZnO NPs. It was concluded that ZnO NPs are activators of
several human PMN functions and that they inhibit apoptosis by a de novo protein synthesis-
dependent and ROS-independent mechanism. In the future, it will be of interest to identify the
nature of proteins that are neo-synthesized in response to ZnO NPs.
7. In vivo infiltration of PMNS induced by NPs using the murine air pouch
model
The effect of different sets of nanoparticles were tested by Vandooren et al. [29] using the
murine air pouch model. The tested NPs were CANs maghemite, type I PEI-CAN-maghemite,
type II PEI-CAN-maghemite, PDMAEMA-SCPNs, PMAAc-SCPNs, PLGA-COOH, PLGA-b-
PEG-COOH, Magh@PNPs, LNP LII, and CAN CIII. All details regarding their characterization
(size, zeta potential, PDI, etc.) are described in their study. When compared with the negative
control (phosphate-buffered saline or PBS), the number of attracted leukocytes were increased
with all NPs, but PMAAc-SCPNs and CAN CIII. The highest count they observed was ∼2.8 x
106 cells/pouch, after treatment with type II PEI-CAN-maghemite NPs vs ∼0.8 x 106 cells/
pouch. Interestingly, for almost all tested NPs, the majority of leukocytes recruited into air
pouch were PMNs (sometime up to ∼90 %). From this study, it was proposed to use the air
pouch leukocytosis model as a future standard assay for an in vivo test for nanoparticles.
Although I am in favor, it is important to mention that the leukocyte infiltration was only
determined after 24 h of treatment, a time point that is probably not the optimal one. As
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previously proposed [118], it is better to perform kinetic experiments with the murine air pouch
model, especially between 3 and 12 h, as we previously documented for determining the effect
of different kinds of agents on inflammation [28, 35, 43, 50, 87, 88, 119]. This is particularly true
for NPs, since their mode of action is still not fully understood. Moreover, time points after 24
h should also be investigated because of lack of knowledge with proinflammatory activity of
NPs in such a model.
The potential proinflammatory activity of iron oxide-containing magnetic nanoparticles
(MNPs) was investigated using the murine air pouch model. Administration of 1,000-MNPs
and 2,000-MNPs (1,000 and 2,000 referring to 1,000 μg or 2,000 μg of iron in terms of CAN
maghemite particles) in C57BL/6 mice induced a prominent influx of leukocytes, mainly PMNs
as determined by differential count and by flow cytometry using anti-CD11b + anti-/Gr-1
antibodies. The neutrophilia was similar to the effect obtained with the positive control
chlorite-oxidized oxyamylose [120]. Since several authors of this study were also authors in
the original work describing the use of the murine air pouch as a standard assay for in vivo
testing of NPs, they did not evaluate the effects of the NPs before the 24 h time point.
Although we have been using the murine air pouch model in our laboratory for ∼13 years for
testing potential effects of different agents on inflammation, it is only recently in 2011 that we
used it to demonstrate for the first time that a given NP, namely, titanium dioxide (TiO2), was
proinflammatory. Indeed, administration of a single dose of TiO2 NPs into the air pouch
attracted leukocytes after 3–9 h, where more than 80 % of cells were PMNs [75]. In addition,
in this study, we reported that TiO2 NPs induced the production of several chemokines locally
present in the air pouch exudates. This model is a simple model that allows investigation of
an acute inflammatory response, the first step leading to chronic inflammation when deregu‐
lation occurs, such as the many studies reporting an increased number of PMNs in the lung/
BALS [98, 99, 121-125]. On the other hand, the fact that an NP possesses some proinflammatory
properties could be of help for the design of drug delivery by NPs for clinical purposes. In this
regard, one can imagine attracting leukocytes such as PMNs into an inflammatory site by a
NP delivering (or coated with) a neutrophil proapoptotic molecule. Although this is specula‐
tive at the moment, this remains an interesting avenue of research that needs to be explored
in the future.
Kinetic and dose-dependent experiments performed with the murine air pouch model of acute
inflammation revealed that, unlike TiO2 used as a positive control in this model, C60(OH)n
(fullerenols) NPs were not proinflammatory in CD-1 mice [126]. To further confirm this negative
result and since, yet, no genetic susceptibility has been reported regarding the biological activity
of NPs, we performed other sets of experiments using C57BL/6 and BALB/c mice. Again, no
significant leukocyte attraction was observed into air pouch. However, after 3 h of treatment,
C60(OH)n NPs were found to amplify the effect of lipopolysaccharides (LPS) causing a rapid
leukocyte influx in which the major cells observed were PMNs. Using an antibody array assay
to detect different analytes present in the exudate led us to conclude that the amplification effect
is explained, at least partially, by an increased local production of several cytokines/chemo‐
kines in the exudates, including the proinflammatory cytokines IL-1β and IL-6. In fact, the profile
of analytes was different in response to LPS alone, C60(OH)n alone, and the mixture of both.
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Using an ELISA to quantify the amount of IL-6, we demonstrated that C60(OH)n increases the
LPS-induced local production of this cytokine. Therefore, although C60(OH)n NPs alone do not
exert proinflammatory activity under certain conditions, they can act in concert with other
agents to cause inflammation, a situation that is likely to occur in vivo. These results further
reinforce that the murine air pouch model is to be performed at different periods of time (kinetic
experiments) as discussed above.
8. Conclusion
Most of the in vitro studies discussed above evaluated the cytotoxicity and/or only one or few
PMN response(s). Yet, no study other than our own has determined the effects of NPs on the
PMN apoptotic rate, a very important process for regulating the number of PMNs. However,
more recent reports have investigated the interaction between NPs and PMNs by studying
different functions/responses, an approach that we encourage. The fact that TiO2 NPs induced
the production of several analytes, including two potent chemokines (IL-8 and Gro-α) is a good
example demonstrating that NPs can indeed target PMNs that, in turn, could attract/activate
other cells [57]. It is highly probable that, in the forthcoming years, several aspects regarding
the effects of different NPs on the biology of human PMNs will be studied. Although there is
a growing interest in developing in vitro assays in nanotoxicology [127], it is also strongly
encouraged to use primary human cells as a source of in vitro cells for testing NPs, since
cancerous cell lines of different origins will complicate data interpretation for the evaluation
of human risk. In addition, determining how a given NP alters inflammation in vivo in other
models than those exclusively targeting the lungs, such as the murine air pouch model, will
help us to better evaluate the potential toxic mechanisms of NPs, especially how they alter the
inflammatory process.
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